Successful Treatment of Chronic Active Epstein-Barr Virus Infection With Recombinant Interleukin-2

Kawa‐Ha, Keisei; Franco, Elia; Doi, Satoru; K, Yumura; Ishihara, Shigehiko; Tawa, Akio; Yabuuchi, Hyakuji

doi:10.1016/s0140-6736(87)91980-5

Cited by 58 publications

(32 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiviral or immunomodulating agents, such as acyclovir, gancyclovir, vidarabine, interferon-␣, and IL-2, have been tried. [30][31][32][33] We reported the adoptive transfer of virus-specific cytotoxic T lymphocytes to a patient with CAEBV infection. 34 However, most of these reports were anecdotal and there are few confirmatory reports.…”

Section: Discussionmentioning

confidence: 99%

Clinical and virologic characteristics of chronic active Epstein-Barr virus infection

Kimura

Hoshino

Kanegane

et al. 2001

Blood

367

417

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical and virologic characteristics of chronic active Epstein-Barr virus infection

Kimura

Hoshino

Kanegane

et al. 2001

Blood

367

417

View full text Add to dashboard Cite

“…[36][37][38] Reduced NK-cell activity has been found in other patients with unusually severe or prolonged EBV infections. [39][40][41][42] Augmented activation of NK cells by recombinant interleukin 2 has been used successfully to treat patients with chronic EBV infection, 43 although it has not so far been used in XLP.…”

Section: Familial Hemophagocytic Lymphohistiocytosismentioning

confidence: 99%

Autoimmunity in human primary immunodeficiency diseases

Arkwright

Abinun

Cant

2002

Blood

162

106

View full text Add to dashboard Cite

Human primary immunodeficiency diseases are experiments of nature characterized by an increased susceptibility to infection. In many cases, they are also associated with troublesome and sometimes life-threatening autoimmune complications. In the past few years, great strides have been made in understanding the molecular basis of primary immunodeficiencies, and this had led to more focused and successful treatment. This review has 3 aims: (1) to highlight the variety of autoimmune phenomena associated with human primary immunodeficiency diseases; (2) to explore how primary immunodeficiencies predispose patients to autoimmune phenomena triggered by opportunistic infections; and (3) to consider the rationale for the current treatment strategies for autoimmune phenomena, specifically in relation to primary immunodeficiency diseases. Reviewing recent advances in our understanding of the small subgroup of patients with defined causes for their autoimmunity may lead to the development of more effective treatment strategies for idiopathic human autoimmune diseases. (Blood. 2002;99:2694-2702

show abstract

“…EBV infects T or NK cells in many severe cases and it is believed that these cells escape immune surveillance because of host deficiency of specific immunity against EBV [4][5][6]; however, the exact pathogenesis is not known. Although several therapies including anti-viral agents, interleukin-2, immunosuppressive drugs, and anti-cancer drugs have been developed [7][8][9][10], they seem to have only a transient effect and are unable to control CAEBV.…”

Section: Introductionmentioning

confidence: 99%

Successful control of Epstein–Barr virus (EBV)‐infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection

et al. 2004

View full text Add to dashboard Cite

Chronic active Epstein-Barr virus infection (CAEBV) is a heterogeneous EBV-related disorder, ranging from mild/moderate forms to rapidly lethal disorders. The lethal form of CAEBV is characterized by multiple organ failure, hemophagocytic syndrome, and development of lymphomas. Allogeneic stem cell transplantation is considered as the only potentially curative treatment for the lethal form of CAEBV, but it is not always desirable because of the high incidence of regimen-related toxicities. A 17-year-old female with CAEBV, who was refractory to conventional therapies and considered to be unable to receive a myeloablative regimen because of multiple organ dysfunction, underwent allogeneic nonmyeloablative stem cell transplantation (allo-NST) before developing a hematological malignancy. She has been well without any signs of CAEBV for 27 months after allo-NST, and we confirmed that specific cytotoxic T lymphocyte activity against EBV was reconstituted. This outcome suggests that allo-NST can control CAEBV by reconstituting the host immunity against EBV. Am.

show abstract

Successful Treatment of Chronic Active Epstein-Barr Virus Infection With Recombinant Interleukin-2

Cited by 58 publications

References 7 publications

Clinical and virologic characteristics of chronic active Epstein-Barr virus infection

Clinical and virologic characteristics of chronic active Epstein-Barr virus infection

Autoimmunity in human primary immunodeficiency diseases

Successful control of Epstein–Barr virus (EBV)‐infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection

Contact Info

Product

Resources

About